Recombinant Yersinia pseudotuberculosis serotype O:3 ArnF is a 128-amino acid protein (UniProt ID: B1JJ34) expressed in E. coli with an N-terminal His tag . It belongs to the undecaprenyl phosphate-aminoarabinose (L-Ara4N) flippase family, critical for modifying lipid A in bacterial lipopolysaccharides (LPS) to confer resistance to cationic antimicrobial peptides and polymyxins .
ArnF partners with ArnE to form a flippase complex that transports undecaprenyl phosphate-α-L-Ara4N across the inner membrane. This modification of lipid A is essential for:
Antimicrobial resistance: Reduces LPS net negative charge, limiting cationic peptide binding .
Virulence regulation: Critical in Yersinia pathogenesis and host immune evasion .
Cloning: Full-length arnF gene cloned into E. coli vectors .
Purification: Affinity chromatography via His-tag, followed by lyophilization .
Mechanistic studies: Used to dissect lipid A modification pathways .
Vaccine development: Engineered Yersinia strains expressing modified lipid A (e.g., MPLA) show enhanced immunogenicity in plague vaccine candidates .
Antimicrobial resistance screening: Target for novel polymyxin adjuvants .
| Species | UniProt ID | Length (aa) | Key Differences |
|---|---|---|---|
| Escherichia coli APEC O1 | A1ADB0 | 128 | 78% sequence identity; lower pLDDT (79.85) |
| Salmonella typhi | Q8Z537 | 125 | Truncated C-terminal; 72% identity |
Genetic knockout studies: ΔarnF mutants in Y. pseudotuberculosis exhibit increased susceptibility to polymyxin B .
Structural insights: Molecular dynamics simulations reveal conformational changes during substrate binding .
Vaccine adjuvants: Recombinant Y. pseudotuberculosis strains producing MPLA-enriched OMVs induce robust immune responses against Y. pestis .
KEGG: ypy:YPK_1837